This page will be updated on a regular basis, and is intended as an overview of some of the current trials of anti-angiogenesis agents. It is not a comprehensive summary of all of the clinical trials ongoing with drugs that inhibit angiogenesis. Therefore, there may be additional trials, and additional sponsors, not represented here. More information can be obtained from the NCI clinical trials database online, where all these studies are listed, or by calling 1-800-4-CANCER regarding trials sponsored by the National Cancer Institute or trials sponsored by drug companies that are voluntarily listed in the database. For information regarding drugs and trials not listed here, you will need to contact the drug company sponsor directly.

The National Cancer Institute (NCI) invites trial sponsors and investigators to submit their trials to the NCI database. If you or your company are interested in participating, see Questions and Answers about Submitting Trials to PDQ for further information and links to an electronic submission form and checklist, that is supported by the NCI. This information is separate from Vidyya and is a link to an outside source.

Drugs that block matrix breakdown:
Drug	Sponsor	Trial	Mechanism	For More Info:
Marimastat	British Biotech; Annapolis, MD	Phase III non-small cell lung, small cell lung, breast cancers.	Synthetic inhibitor of matrix metalloproteinases (MMPs)	800-355-6957 or 800-4-CANCER Online Information
AG3340	Agouron; LaJolla, CA	Phase II glioblastoma multiforme.	Synthetic MMP inhibitor	888-849-6482 or 800-4-CANCER Online Information
COL-3	Collagenex; Newtown, PA	Phase I/II brain.	Synthetic MMP inihibitor. Tetracycline® derivative	800-4-CANCER Online Information
Neovastat	Aeterna; Québec	Phase III renal cell (kidney) cancer, Phase III non-small cell lung cancer.	Naturally occurring MMP inhibitor	888-349-3232 Online Information
BMS-275291	Bristol-Myers Squibb; Wallingford, CT	Phase II/III Advanced or Metastatic Non-Small Cell Lung.	Synthetic MMP inhibitor	203-677-6779 Online Information

Drugs that inhibit endothelial cells directly:
Drug	Sponsor	Trial	Mechanism	For More Info:
Thalidomide	Commercially available, approved for leprosy; Celgene	Phase I/II for advanced Melanoma, Phase II head and neck cancer, ovarian, metastatic prostate, and Kaposi's sarcoma; Phase II with chemotherapy against solid tumors; adjuvant study in recurrent or metastatic colorectal cancer; Phase II Graft vs Host Disease; Phase II gynecologic sarcomas, liver cancer; multiple myeloma; CLL, Recurrent or Progressive Brain, Phase III non-small cell lung, nonmetastatic prostate, refractory multiple myeloma, renal cancer.	Unknown	732-805-3905 or 800-890-4619 ext. 3905 or 800-4-CANCER Online Information
Squalamine	Magainin Pharmaceuticals; Plymouth Meeting, PA	Phase II non small cell lung cancer; Phase II Ovarian; Phase I Advanced Cancers.	Extract from dogfish shark liver; inhibits sodium-hydrogen exchanger, NHE3	610-941-4020 or 800-4-CANCER Online Information (Link to Magainin Web site)
Endostatin	EntreMed; Rockville, MD	Phase I solid tumor studies.	Inhibition of endothelial cells	University of Wisconsin 800-622-8922 M.D. Anderson Cancer Center 800-392-1611 Dana-Farber Cancer Institute 617-632-5100 Online Information

Drugs that block activators of angiogenesis:
Drug	Sponsor	Trial	Mechanism	For More Info:
SU5416	Sugen; South San Francisco, CA	Phase I recurrent head & neck, advanced solid tumors, stage IIIB or IV breast cancer; Phase I advanced malignancies, recurrent or progressive brain(pediatric); Ovarian, Phase I with chemotherapy against solid tumors; Phase I/II AML; Phase I/II glioma, advanced malignancies, advanced colorectal, Phase II von-Hippel Lindau disease, advanced soft tissue; Phase II prostate cancer, colorectal cancer, metastatic melanoma, multiple myeloma, malignant mesothelioma: metastatic renal, advanced or recurrent head and neck, Phase III metastatic colorectal cancer.	Blocks VEGF receptor signaling	800-SUGEN-06 or 650-553-8678 or 800-4-CANCER Online Information
SU6668	Sugen; South San Francisco, CA	Phase I against advanced tumors.	Blocks VEGF, FGF, and PDGF receptor signaling	800-SUGEN-06 or 650-553-8678 Online Information (Link to Sugen Web site)
Interferon-alpha	Commercially available	Phase II/III (search* NCI trials database for listings).	Inhibition of bFGF and VEGF production	800-4-CANCER
Anti-VEGF Antibody	National Cancer Institute, Bethesda, MD; Genentech, San Francisco, CA	Phase I refractory solid tumors. Phase II metastatic renal cell cancer.	Monoclonal antibody to vascular endothelial growth factor (VEGF)	888-624-1937 or 800-4-CANCER Online Information

*When searching for interferon-alpha trials in the NCI database, select "cytokine therapy," rather than "antiangiogenesis therapy," in the modality field.

Drugs that inhibit endothelial-specific integrin/survival signaling:
Drug	Sponsor	Trial	Mechanism	For More Info:
EMD121974	Merck KCgaA; Darmstadt, Germany	Phase I in patients with advanced or metastatic cancer, Phase I in patients with HIV related Kaposi's Sarcoma, Phase I/II progressive or recurrent Anaplastic Glioma	Small molecule blocker of integrin present on endothelial cell surface	800-4-CANCER Online Information

Drugs with non-specific mechanism of action:
Drug	Sponsor	Trial	Mechanism	For More Info Call:
CAI	National Cancer Institute, Bethesda, MD	Phase I studies in combination against solid tumors; Phase II ovarian cancer; advanced renal cell cancer, metastatic renal cell cancer, Phase III non-small cell lung cancer.	Inhibitor of calcium influx	800-4-CANCER or 888-624-1937 Online Information
Interleukin-12	Genetics Institute; Cambridge, MA	Phase I/II Kaposi's sarcoma; Phase I/II Interleukin-12 gene therapy.	Up-regulation of interferon gamma and IP-10	800-4-CANCER Online Information
IM862	Cytran; Kirkland, WA	Phase I recurrent ovarian cancer; Phase II for untreated metastatic cancers of the colon and rectal; Phase III Kaposi's sarcoma.	Unknown mechanism	425-889-5808 or 800-4-CANCER Online Information